Equivir G

**Equivir G** is an investigational prescription antiviral formulation consisting of the Equivir FDA Generally Recognized as Safe eligible polyphenol blend with added gallic acid. It is being developed as a broad-based antiviral candidate for respiratory viral infections and other viral diseases. Public sponsor materials describe demonstrated antiviral activity, but do not disclose a validated molecular target, specific viral protein target, or clinical efficacy for Equivir G. Global Research and Discovery Group originated the proprietary compounds; Global BioLife and Impact BioMedical have held development rights, while ProPhase Labs obtained worldwide development and commercialization rights and stated that it intended to prepare an FDA Investigational New Drug application for Equivir G. ([impactbiomedinc.com](https://www.impactbiomedinc.com/equivir/))

Other names

Equivir GEquivir-G